Skip to content
LUCEM

EXPLORE LUCEM

EMERGING HEALTH INSIGHTS
FOR A BRIGHTER TOMORROW

MOTS-c

The mitochondrial peptide attracting attention for exercise endurance, energy and metabolic health. Here is what studies actually show, what users report, and what people discuss about taking it.

START HERE · PLAIN ENGLISH

Mitochondria are the parts of your cells that help turn food into usable energy. MOTS-c is a small peptide encoded by mitochondrial DNA. Researchers are studying how it relates to exercise and metabolism; online communities are experimenting with injected MOTS-c for stamina, energy and body composition. Those are two different kinds of evidence.

What is it?A naturally occurring, 16-amino-acid peptide encoded in mitochondrial DNA — discovered in 2015 — that your body already produces and releases from skeletal muscle, especially during exercise.12
Why are people interested?Metabolic health and insulin sensitivity are the main draw, with growing interest in exercise/muscle aging, bone health, and general mitochondrial/longevity framing.12
Human researchNo completed trial of injected MOTS-c has been published. One Phase 2a trial is currently recruiting (not yet reported); a related but distinct analog compound completed early-phase testing; several observational studies measure naturally occurring MOTS-c as a biomarker.3132122
Animal & lab researchExtensive since 2015 — metabolic, muscle, bone, cardiac and other models, mostly from mouse and rat studies.11516171819
Development & regulatory statusInvestigational, not FDA-approved for any use. In an unusual position as of 2026: recently removed from an FDA "do not compound" list, and an FDA advisory committee has recommended — but the FDA has not yet finalized — adding it to the list of substances licensed pharmacies can legally compound.4678

Why People Explore MOTS-c

Energy, exercise performance and metabolic health are the main attractions. Each card separates animal or observational research from the experiences people post online.

Metabolic Health, Blood Sugar & Weight

Evidence: Mostly Animal & Lab Research

What the Research Says

This is the finding that put MOTS-c on the map. In the peer-reviewed study that first described it (Lee et al., Cell Metabolism, 2015), injecting MOTS-c into mice prevented both age-related and high-fat-diet-induced insulin resistance, and prevented diet-induced obesity.1 That result has since been extended by other labs in additional mouse and rat models. What doesn't exist yet: any completed, published trial testing injected MOTS-c for weight, blood sugar or insulin sensitivity in people. A Phase 2a, randomized, placebo-controlled trial (NCT07505745, sponsor Hudson Biotech) is currently recruiting adults with prediabetes and overweight/obesity to test exactly this — it started enrolling in February 2026 and had not reported results as of this build.3 Separately, several human observational studies have measured naturally circulating MOTS-c and found lower levels associated with insulin resistance and metabolic dysfunction — association, not a test of the peptide as treatment.2122

What the Real World Says

Metabolic health and weight are the main reasons MOTS-c comes up in longevity and biohacking discussion, often described as an "exercise mimetic." Dr. William Seeds, a board-certified surgeon and prominent peptide-medicine educator, has discussed MOTS-c in podcast and lecture appearances as part of his broader peptide-therapy teaching, describing it in terms of metabolic optimization and fat loss.27 This is attributable professional commentary, not a controlled study or a peer-reviewed publication — no peer-reviewed research paper by Dr. Seeds specific to MOTS-c was located. Worth knowing when weighing it: Dr. Seeds' primary published material on peptides is a self-published practitioner handbook issued through his own institute, and he founded and runs a commercial peptide-medicine education and certification business (including a physician "mastermind" program and clinical practices) — he has a direct financial interest in peptide therapy's adoption by other clinicians, separate from whether any specific peptide works. Beyond this, independent, structured real-world reporting is thin: most of what's easy to find online is written by sellers or clinics offering it, rather than independent community analysis. See Real World Says under Safety, below, for what little independent signal exists.

See the ResearchStudies, numbers and limits

The foundational mouse study

Lee et al. (2015) found MOTS-c's primary target tissue is skeletal muscle, where it inhibits the folate cycle, raises AICAR, and activates AMPK — the same energy-sensing pathway exercise activates. MOTS-c-treated mice were protected from both diet-induced and age-related insulin resistance and from diet-induced obesity.1

The Phase 2a trial

NCT07505745 is a Phase 2a, randomized, double-blind, placebo-controlled study (est. 120 participants, ages 18–65, BMI 27–40) testing 12 weeks of MOTS-c versus placebo in adults with prediabetes, with a 4-week safety follow-up. Primary completion is estimated for February 2027.3

Limitations

  • No human dosing, safety, or efficacy data for injected MOTS-c has been published as of this build — the entire efficacy case currently rests on animal studies.4
  • Much of the foundational research comes from one research group (the discoverers' own lab); the senior author has disclosed a financial relationship (consultant/stockholder) with a company developing a MOTS-c analog, which is worth knowing when weighing the literature.23
  • Observational human biomarker studies show association with metabolic dysfunction, not that giving someone MOTS-c would fix it.2122

Exercise & Muscle Aging

Evidence: Some Human Evidence

What the Research Says

MOTS-c is sometimes called an "exercise mimetic" because your body's own levels of it rise sharply with exercise — a peer-reviewed human study (Reynolds et al., Nature Communications, 2021) found endogenous MOTS-c rose roughly 12-fold in skeletal muscle after acute exercise, and that levels decline with age.2 Importantly, that human finding is a measurement of your body's own MOTS-c, not a trial of injecting it — the same paper's mouse experiments (where MOTS-c actually was administered) found it improved physical performance and muscle homeostasis with age.2

What the Real World Says

People in longevity and performance-focused communities are drawn to this angle specifically — the idea of restoring an exercise-associated signal that declines with age. We didn't find independent, structured reporting substantial enough to characterize how people's actual experience compares to this mechanism.

See the ResearchStudies, numbers and limits

Reynolds et al. (2021) is the key human data point behind MOTS-c's "exercise mimetic" framing: it establishes that exercise induces MOTS-c in people, and that this natural induction declines with age — but it did not test administering MOTS-c to humans.2

A separate, peer-reviewed randomized trial (Dieli-Conwright et al., Scientific Reports, 2021; n=49 breast cancer survivors) tested a 16-week aerobic-and-resistance exercise program and measured its effect on circulating MOTS-c, finding the exercise-MOTS-c relationship also held in this population and appeared to differ somewhat by ethnicity. This is another study of exercise's effect on the body's own MOTS-c, not of administering the peptide.24

Bone Health

Evidence: Mostly Animal & Lab Research

What the Research Says

Bone is the second use the FDA is formally evaluating MOTS-c for (alongside obesity), and the supporting evidence is entirely preclinical.5 Multiple independent lab groups have found MOTS-c promotes osteoblast activity (the cells that build bone) and inhibits osteoclast activity (the cells that break it down) in rat and mouse models, including a mouse model of estrogen-loss-related bone loss.1516 No human bone-density or fracture trial exists.

What the Real World Says

We found no meaningful independent real-world discussion specific to bone health — this appears mainly as a research/regulatory topic rather than something people report on individually.

See the ResearchStudies, numbers and limits

In an ovariectomized-mouse model (a model of estrogen-loss-related bone loss), daily MOTS-c injection for 12 weeks significantly reduced bone loss on micro-CT imaging, working partly by inhibiting RANKL-driven osteoclast differentiation through an AMPK-dependent mechanism.16

A separate mouse study found MOTS-c reduced pain behavior in a cancer-induced bone pain model, proposed to work through AMPK-driven mitochondrial biogenesis — a different bone-related question (pain, not density) from the osteoporosis studies above.28

Separate cell-culture and rat studies found MOTS-c promotes osteoblast proliferation and collagen synthesis via the TGF-β/Smad signaling pathway, and accelerates fracture healing in bone-marrow stem cell models.15

Other Areas People Talk About

Liver Fat (via a related analog compound)

Research: A chemically modified, longer-acting MOTS-c analog called CB4211 (developed by CohBar, a company co-founded by MOTS-c's discoverer) completed a Phase 1a/1b randomized, placebo-controlled trial in people with obesity and fatty liver disease (NAFLD). The company announced positive topline results — improvements in markers of liver injury and metabolism — as a conference abstract (Hepatology, 2021); it does not appear to have been published as a full peer-reviewed paper, and the trial's further development doesn't appear to have continued.1310 Important distinction: CB4211 is a modified analog, not unmodified MOTS-c — its results don't directly transfer to the native peptide sold online.

Real World: Not discussed as a distinct topic in community discussion — liver fat doesn't come up independently of general metabolic-health interest.

Heart & Metabolic-Stress Protection

Research: Animal studies report MOTS-c helps restore cardiac function in diabetic rats, protects lung tissue from radiation injury in mice, and — in a separate mouse study — protected against heart failure caused by pressure overload, partly by reducing cell death in stressed heart cells.171825 These are lab-model findings from several independent groups, not human data.

Real World: Not a topic we found independent real-world discussion of.

Immune Function & Host Defense

Research: A 2026 peer-reviewed study from MOTS-c's original discovery lab (Rice, Lee, and colleagues, eLife) found MOTS-c has direct antimicrobial activity — fully neutralizing MRSA bacterial infection in a mouse model — and reprograms immune cells (monocytes) toward enhanced bacterial clearance. This is a newer research direction, entirely preclinical, reframing MOTS-c as a possible host-defense peptide in addition to its metabolic roles.26

Real World: Too new and too preclinical to have generated independent real-world discussion as of this build.

Biomarker Research (Not a Treatment Use)

Research: A growing number of human observational studies measure naturally circulating MOTS-c levels as a biomarker — not as a treatment — in conditions including multiple sclerosis, kidney-transplant cardiovascular risk, peritoneal dialysis, and heart-attack-related injury, generally finding lower circulating MOTS-c associated with worse markers of disease.2122 These studies say something about MOTS-c as a signal the body produces; they are not evidence that administering more of it would change outcomes.

Real World: This is research-community discussion (via published studies), not public/patient discussion — included here for completeness since it's a genuine and growing part of the literature.

Real-World Use: What People Are Actually Discussing

A scan-first guide to the questions that keep appearing in peptide communities. These are documented self-reports and published online protocols, not prescriptions or tested human regimens. Links point to the original discussions so you can see the context.

What draws people in

Workout stamina, less fatigue, energy, weight-management interest and a hoped-for “exercise mimetic” effect.

What people also report

Sometimes no benefit, sometimes fatigue rather than energy, plus soreness, itching, headache, appetite changes or feeling unwell.

Anecdotal amounts and frequencyWhy you see radically different numbers online›

What the community says

Recent first-person discussions describe very different self-experiments: roughly 0.4–1 mg on some days, 1–2 mg daily, or 2.5–5 mg per administration once to several times weekly. Some posters describe still higher amounts. These are reported practices, not a consensus, and the variation itself is an important finding. 303132

Research says

There is no established, validated human dose, frequency or dose-response curve for injected native MOTS-c. Animal-study doses cannot simply be translated into a personal protocol. The FDA’s 2026 review highlighted the absence of human administration and safety data. 429

Timing, exercise and fastingMorning or evening? Before a workout? Empty stomach?›

What the community says

Morning and pre-workout use come up frequently because people are seeking energy or endurance. Others report feeling sedated and moving their experiments to evenings. One poster reported feeling awful while fasted on rest days but much better after breakfast and exercise, while acknowledging food and training could explain the difference. 3334

Research says

Exercise can increase the body’s own MOTS-c, but that does not establish the ideal time to inject a product. No controlled human study has established that fasted, fed, morning or pre-workout administration improves outcomes. 24

Cycles, breaks and stackingShort experiments, longer runs and SS-31 comparisons›

What the community says

People describe everything from a few weeks to longer daily experiments, sometimes with breaks. SS-31, NAD+, GLP-1 drugs and other peptides appear in the same discussions. Several users note that when they start multiple compounds or change training at once, it is impossible to tell what caused a result. 303135

Research says

No human evidence establishes an effective cycle length, a necessary “receptor reset,” or a safe stacking schedule for MOTS-c. Combining unstudied compounds makes both benefits and adverse effects harder to attribute. 29

Reported results: the good, the neutral and the badWhat first-person accounts actually describe›

What the community says

Some users describe unusually good cardio sessions, less perceived exertion or sharper focus. Others report an impressive first experience followed by diminishing effects, no change, or outright fatigue and a sedated feeling. Body-fat changes are harder to interpret because many posters are also dieting, exercising or using other drugs. 333435

Research says

Animal studies support interest in metabolism and age-related physical performance. Measurements of naturally occurring MOTS-c in people are not proof that injecting it improves energy, fitness or weight. Self-reports cannot separate placebo effects, training changes, product differences or other medications. 1229

Side effects and reactions people mentionIncluding reports that contradict the “more energy” narrative›

What the community says

First-person accounts mention injection-site stinging, persistent itching or bumps, headache, nausea or feeling unwell, dizziness, fatigue, anxiety-like stimulation and sometimes unusually strong hunger. Individual rash reports also exist. These are signals to investigate, not verified incidence rates or proof that MOTS-c caused every symptom. 30323637

Research says

The FDA found insufficient clinical and nonclinical safety information, no human drug-product administration data and an unresolved ability to assess immunogenicity (the possibility of an immune reaction). The long-term risks, interactions and rates of adverse effects remain unknown. 29

Formulation, injection and product qualityWhy vial discussions are not the same as clinical instructions›

What the community says

Most online accounts concern injected, often lyophilized (freeze-dried) products; people discuss reconstitution, concentration and injection-site reactions. Those posts do not establish sterility, identity, stability or a universally safe preparation method. 32

Research says

A peptide’s identity, purity, endotoxin level and sterile handling are separate questions from whether its proposed biological mechanism is plausible. Products sold for research are not interchangeable with regulated clinical trial materials. 412

The Takeaway

IN ONE MINUTE

MOTS-c is an interesting mitochondria-linked peptide with meaningful animal research and a clear reason for interest in exercise and metabolism. Online experiences are unusually mixed: some report striking workout energy, while others report little effect, fatigue or injection reactions. The human benefits, appropriate regimen and long-term safety of injected MOTS-c have not been established.

What About Safety?

What We Know

  • MOTS-c is a peptide your body already produces naturally, and no acute toxicity has been reported in the animal literature at doses studied.1 Beyond that, there isn't much to report as established: no peer-reviewed human safety database for administered MOTS-c exists as of this build.4
  • Self-experimenters have described adverse effects including increased heart rate, palpitations, injection-site reactions, sleep disturbance, and fever, according to a peptide-testing and anti-doping-focused organization's review of anecdotal reports.14 This is isolated, self-reported signal — it doesn't establish a rate or a confirmed cause, and may reflect the product used as much as the peptide itself.14

What We Don't Know

  • Human pharmacokinetics (how fast it's absorbed, how long it lasts, what dose does what) are unknown — no published human dosing study exists for native MOTS-c.4
  • Long-term effects of repeated administration in people are entirely unstudied.
  • MOTS-c's relationship to cancer risk is genuinely unresolved and more complex than a simple yes/no: one peer-reviewed study found lower natural MOTS-c levels associated with worse outcomes in ovarian cancer patients, and that adding MOTS-c suppressed cancer-cell growth in lab experiments — the opposite of a risk signal in that specific context.20 This doesn't establish MOTS-c is protective against cancer generally, and it doesn't establish it's risky either — it's simply not settled.

Reported / Identified Concerns

  • FDA reviewers who evaluated MOTS-c for the compounding pathway described in their briefing document that available products aren't well characterized from a physical/chemical standpoint, and that the evidence base doesn't yet support a reasonable expectation of safety for compounding purposes — this was echoed by advocacy groups who testified against inclusion.94
  • Products sold online "for research purposes only" are not manufactured or quality-controlled for human use, and identity/purity cannot be assumed.11
  • MOTS-c is prohibited at all times in Olympic and other WADA-governed sport, with no Therapeutic Use Exemption available — a real career consequence for competitive athletes, independent of any health question.11

Is It Approved or Legal?

Status as of September 2026 — this is a fast-moving, actively contested regulatory situation; verify before relying on it.

United States (FDA)

Investigational — in regulatory limbo

Not approved for any use. In September 2023, the FDA placed MOTS-c (with about 18 other peptides) into "Category 2," a designation that effectively barred compounding pharmacies from using it, citing safety concerns including limited human data.12 In April 2026, following public pressure from HHS Secretary Robert F. Kennedy Jr., the FDA removed MOTS-c and 11 other peptides from Category 2 — but this did not place it on the "may compound" Category 1 list, leaving its compounding status unresolved.89 On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed MOTS-c for possible inclusion on the 503A Bulks List (for obesity and osteoporosis). FDA's own scientific reviewers had recommended against inclusion, citing insufficient safety, efficacy and chemical-characterization data — but the PCAC (an outside advisory body, not FDA staff) voted to recommend it anyway, overriding that staff recommendation, alongside five of the six other peptides reviewed that week.410 This disagreement between FDA's own reviewers and its advisory committee is unusual and worth understanding on its own terms: the PCAC's vote is a recommendation, not a decision, though the agency has historically tended to follow PCAC recommendations. The FDA had not issued a final determination as of this build.4567

Canada

Not authorized

Health Canada has explicitly named MOTS-C among unauthorized injectable peptide products in its public advisories on peptides sold online, warning that such products haven't been assessed for safety, efficacy or quality and are illegal to sell in Canada.12

Sport / WADA

Prohibited at all times

MOTS-c is banned under WADA's Prohibited List, Section S4.4 (Hormone and Metabolic Modulators — AMPK activators), with no Therapeutic Use Exemption available since there's no approved therapeutic use to exempt.11

What We Still Don't Know

Does injected MOTS-c actually do anything beneficial in people?

This is genuinely unknown — every efficacy finding to date comes from mice and rats. The ongoing Phase 2a trial (NCT07505745) is the first real attempt to answer this for metabolic outcomes, and it hasn't reported.3

Will the FDA finalize the PCAC's recommendation to allow compounding?

Not yet known — and less straightforward than it might seem. FDA's own staff reviewers recommended against including MOTS-c, but the PCAC voted to recommend it anyway. Whether the agency's final decision follows its own scientists or its advisory committee is genuinely unresolved as of this build.410

Does gray-market MOTS-c actually match the peptide studied in mice?

FDA reviewers themselves raised this as a concern in their briefing document, describing available products as not well characterized chemically — there's no independent assurance that what's sold online matches native MOTS-c in identity or purity.4

What does MOTS-c's relationship to cancer actually look like?

Unresolved and more nuanced than a simple risk statement either way — see What We Don't Know under Safety, above.20

What would a real human dose even be?

There's no validated human dose because there's no completed human dosing study — anything describing a specific milligram amount for people is extrapolated from animal studies or community practice, not established clinical data.

Quality Matters Too.

Whether the research supports a compound, and whether a specific product actually contains what its label says, are two separate questions. For MOTS-c specifically, FDA chemistry reviewers examining it for the compounding pathway found that available MOTS-c products aren't well characterized from a physical and chemical standpoint — a concern raised directly in the agency's own briefing document, not just by outside critics.4

That means, for MOTS-c more than for some other peptides, the basic question of "is this actually what the label says it is" is not yet reliably answerable from outside a controlled clinical setting.

Explore Safety & Quality →

Research & References

Every claim on this page traces back to these sources. Open the studies and regulatory documents yourself.

HOW WE RATE THE EVIDENCE →
  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454 — peer-reviewed, the foundational study.Lee et al., Cell Metabolism 2015 (PMC)
  2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470 — peer-reviewed; human portion is an observational measurement of endogenous MOTS-c, not an administration trial.Reynolds et al., Nature Communications 2021 (cited via USADA)
  3. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity, NCT07505745 — registered Phase 2a trial, sponsor Hudson Biotech, recruiting as of this build, results not yet reported.ClinicalTrials.gov, NCT07505745
  4. FDA Evaluation of MOTS-c-Related Bulk Drug Substances (MOTS-c free base and MOTS-c acetate) — briefing document prepared for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. Primary FDA source.FDA PCAC Briefing Document, May 2026
  5. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — confirms MOTS-c evaluated uses as obesity and osteoporosis.FDA advisory committee calendar
  6. FDA advisory committee backs two more peptides, rejects one for compounding list — trade-press coverage confirming the PCAC's favorable vote on MOTS-c, BPC-157, KPV and TB-500.RAPS (Regulatory Affairs Professionals Society)
  7. FDA Advisory Committee Endorses Compounding of Certain Peptides — law-firm summary of the July 2026 PCAC vote and its practical meaning (recommendation only, not a final rule).Holland & Knight
  8. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings — law-firm summary of the April 2026 Category 2 removal, the HHS Secretary's public comments, and the important caveat that removal did not place these peptides on the Category 1 "may compound" list.Orrick
  9. FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" List — corroborating law-firm coverage of the same April 2026 action and its regulatory-limbo effect.Frier Levitt
  10. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting — law-firm coverage of the July 2026 PCAC meeting, prior Category 2 history, and the specific fact that FDA's own scientific reviewers recommended against including BPC-157, KPV, TB-500, MOTS-c and other reviewed peptides on the 503A Bulks List (citing insufficient safety, efficacy and chemical-characterization data), while the PCAC voted to recommend inclusion for MOTS-c and five of the six other peptides anyway, overriding that staff recommendation.McDermott Will & Emery
  11. What is the MOTS-c peptide? — official anti-doping guidance confirming WADA Prohibited List status (Section 4.4, AMPK activators) and unavailability of a Therapeutic Use Exemption.USADA (U.S. Anti-Doping Agency)
  12. Think twice before injecting peptides bought online: unauthorized products can seriously harm you — Health Canada public advisory explicitly naming MOTS-C among unauthorized injectable peptide products.Health Canada
  13. Testimony Before the FDA's Pharmacy Compounding Advisory Committee Regarding Placing MOTS-c on the 503A Bulks List — advocacy-group (Public Citizen) opposition testimony, citing FDA scientists' product-characterization concerns and the CB4211/Hepatology 2021 conference-abstract citation.Public Citizen testimony, July 2026
  14. MOTS-c: A 16-Amino-Acid Mitochondrial-Derived Peptide and AMPK Activator — secondary summary citing self-experimenter anecdotal adverse-effect reports and the absence of a peer-reviewed human safety database.Superpower Health
  15. MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway — peer-reviewed rat/cell-culture study.European Review for Medical and Pharmacological Sciences
  16. MOTS-c protects against ovariectomy-induced bone loss via AMPK-dependent inhibition of RANKL-driven osteoclastogenesis — peer-reviewed mouse study.Peer-reviewed mouse osteoporosis study, via Infona
  17. Li S, Wang M, Ma J, et al. MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats. Front Endocrinol. 2022 — peer-reviewed, animal.Li et al., Frontiers in Endocrinology 2022 (PMC)
  18. Zhang Y, Huang J, Zhang Y, et al. The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism. Antioxidants. 2024 — peer-reviewed, animal/cell.Zhang et al., Antioxidants 2024 (PMC)
  19. Kong BS, Lee H, L'Yi S, Hong S, Cho YM. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Exp Mol Med. 2025 — peer-reviewed, animal.Kong et al., Experimental & Molecular Medicine 2025 (PMC)
  20. Yin Y, Li Y, Ma B, et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Advanced Science. 2024 — peer-reviewed; includes both human tissue correlation and lab experiments.Yin et al., Advanced Science 2024 (PMC)
  21. Comparison of Serum MOTS-c Levels in Patients With Multiple Sclerosis and Healthy Controls — peer-reviewed human observational/biomarker study.Peer-reviewed human biomarker study, via PMC
  22. MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study — peer-reviewed human observational/biomarker study.Peer-reviewed human biomarker pilot study, via PMC
  23. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction — peer-reviewed paper whose author disclosures note the senior MOTS-c researcher's consulting/stockholder relationship with CohBar Inc., the company developing the MOTS-c analog CB4211.Author disclosure, via PMC
  24. Dieli-Conwright CM, Sami N, Norris MK, Wan J, Kumagai H, Kim SJ, Cohen P. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Sci Rep. 2021;11:16916 — peer-reviewed randomized trial of exercise (not MOTS-c administration).Dieli-Conwright et al., Scientific Reports 2021 (PMC)
  25. Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice — peer-reviewed, Renmin Hospital of Wuhan University.Peer-reviewed mouse heart-failure study, via PMC
  26. Rice MC, Imun M, Jung SW, et al. MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide. eLife. 2026 — peer-reviewed, includes MOTS-c's original discoverer (Changhan Lee) as senior author; mouse and human-cell antimicrobial/immune findings.Rice et al., eLife 2026 (PMC)
  27. Peptides and Cellular Medicine Part 2 with Dr. William Seeds (podcast/lecture appearance) — professional commentary from a named peptide-medicine practitioner, not a study. Cross-checked against Dr. Seeds' broader public/commercial footprint: he is a board-certified surgeon; founder of the Seeds Scientific Research & Performance Institute and the International Peptide Society; faculty for the A4M Peptide Certification Program; and author of a self-published practitioner handbook ("Peptide Protocols: Volume One," Seeds Scientific Performance Research, 2020) issued through his own institute rather than a peer-reviewed press. No peer-reviewed journal publication specific to MOTS-c by Dr. Seeds was located.Optimization Academy podcast, featuring Dr. William Seeds
  28. MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis — peer-reviewed mouse study.Peer-reviewed mouse bone-pain study, via PMC
  29. FDA, July 2026, MOTS-c clinical safety conclusionsOpen original source
  30. Reddit r/Biohacking, July 31 2026: MOTS-C dosing and resultsOpen original source
  31. Reddit r/PeptideGuide, September 22 2026: dosing and frequency discussionOpen original source
  32. Reddit r/PeptideGuide, September 14 2025: mixed MOTS-c experienceOpen original source
  33. Reddit r/PeptideGuide, March 14 2026: MOTS-c and SS-31 experienceOpen original source
  34. Reddit r/Biohacking, August 26 2026: fasted vs fed experiencesOpen original source
  35. Reddit r/Biohacking, August 1 2026: exercise reportOpen original source
  36. Reddit r/Biohacking, August 23 2026: rash and skin reactionsOpen original source
  37. Reddit r/PeptideGuide, September 10 2026: fatigue, hunger and itchingOpen original source

Where to Next?

Safety & QualityHow to Read a Peptide COAExploreSee All Peptides A–ZLearnHow We Grade the Evidence

Still Confused?

Peptide research can get complicated quickly. If you'd rather talk it through with someone who can help you understand the terminology, research and questions worth asking:

General education only — not medical advice.

GET HELP UNDERSTANDING YOUR OPTIONS